Abstract
Abstract
Background
A quality by design approach can potentially lead to a more robust/rugged method development due to emphasis on the risk assessment and management. By carefully understanding the step-by-step procedure for analytical QbD-based optimization parameters, such as analytical target profile and critical quality attributes (CQAs), was assessed. The present study describes the simple, rapid, sensitive and cost-effective RP-HPLC method development and validation for the estimation of evogliptin tartrate in pharmaceutical dosage form.
Results
The factor screening studies were performed using Box–Behnken design by three key components of the RP-HPLC method (mobile phase, pH and flow rate). The chromatographic conditions were optimized with the Design Expert software trial version 13.0. The optimal chromatographic separation was achieved having water C18 column (250 mm × 4.6 mm, 5 μ) and using mobile phase as a methanol and phosphate buffer (pH 4.5) 60:40% v/v with a flow rate 1.0 ml/min and UV detection at 267 nm. The Box–Behnken experimental design describes the interrelationship of mobile phase, pH and flow rate at three different levels, and responses of retention time and tailing factor were observed with response surface plot and statistical data. The developed method was validated as per recommended ICH guidelines which revealed the high degree of linear, precise, accurate, sensitive and robust method over the existing RP-HPLC method for evogliptin tartrate.
Conclusion
The developed QbD-based method helped in generating a design space and operating space with knowledge of all method performance characteristics, and RP-HPLC method takes less time and can be used in the industry for routine quality control of bulk and marketed formulation of evogliptin tartrate.
Publisher
Springer Science and Business Media LLC
Reference23 articles.
1. Tan X, Hu J (2016) Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type-2 diabetes. Expert Opin Pharmacother 17(9):1285–1293
2. Thakkar K, Patel K et al (2021) Evogliptin a new drug of DPP-4 inhibitor: an overview. World J Pharm Res 5(10):1921–1929
3. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M (2015) Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38(1):140–149
4. Kim M-J, Kim N-Y et al (2018) Evogliptin, a dipeptidyl peptidase-4 inhibitor, attenuates renal fibrosis caused by unilateral ureteral obstruction in mice. Diabetes Meta J 43(1):271–278
5. Rodbard HW, Jellinger PS, Davidson JA (2009) Statement by an American Association of Clinical Endocrinologists American college of Endocrinology consensus penal on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 15(6):540–559
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献